An activatable cell-penetrating peptide delivered the immune drug resiquimod to tumors at 1,000-fold higher concentration than surrounding tissue, achieving localized anti-tumor efficacy through systemic delivery.
1,000x tumor selectivityActivatable CPP achieved over 1,000-fold higher drug concentration in tumor tissue compared to surrounding normal tissue after systemic injection
What the researchers found
ACPP-resiquimod conjugate achieved >1,000-fold greater tumor tissue concentration than surrounding normal tissue after systemic delivery. Therapeutic efficacy matched localized free resiquimod in syngeneic murine tumors. Dual enzymatic activation: MMP-2/9 cleavage + cathepsin B release.
Why it matters
Many powerful immune drugs are too toxic for systemic use. This precision peptide delivery achieves the impossible — systemic injection with localized tumor effects — potentially making potent immune modulators safe enough for clinical cancer therapy.
The numbers in context
>1,000-fold tumor selectivity; MMP 2/9 activated; cathepsin B release; systemic = local efficacy
How the study worked
Preclinical study. Activatable CPP designed with MMP-2/9 cleavage site and cathepsin B-cleavable linker for resiquimod. Tissue biodistribution measured. Anti-tumor efficacy tested in syngeneic murine tumor models with systemic delivery.
Who was studied
Mice with syngeneic tumors
What this study cannot tell us
Mouse tumor models only. MMP expression varies between human tumors. Drug payload limited to resiquimod in this study. Manufacturing complexity of peptide-drug conjugates. Long-term safety not assessed.
How to read the evidence
Moderate evidence: preclinical study with impressive biodistribution data and therapeutic efficacy in murine tumors. No human data.
When this study was published
Published 2021. Activatable CPP and peptide-drug conjugate technologies are advancing toward clinical cancer applications.
The bigger picture
Activatable CPPs represent a breakthrough in targeted cancer therapy. By using the tumor's own enzymes to activate the delivery peptide, this approach eliminates off-target toxicity — the main barrier to many powerful immune therapies.
Questions still open
- Can this ACPP platform deliver other immune modulators or chemotherapy drugs to tumors?
- Would it work in human tumors with variable MMP expression?
- Could ACPP-drug conjugates replace intratumoral injections that currently require direct tumor access?
Common questions
How does the peptide know to activate only in tumors?
Why is 1,000x selectivity important?
Read the original research
Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.
Pharmaceutics, 13(3)
Citation
Hingorani, Dina V; Camargo, Maria F; Quraishi, Maryam A; Adams, Stephen R; Advani, Sunil J. (2021). Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.. Pharmaceutics, 13(3). https://doi.org/10.3390/pharmaceutics13030365